In Vitro Assay for Predicting Alzheimer's Disease Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) pre-symptomatically, complicating therapeutic interventions and clinical trial evaluations due to the progressive nature of cognitive decline and the lack of direct measurement tools for hippocampal neurogenesis.
Innovation Solution
An in vitro cell-based assay that cultures human hippocampal progenitor cells in serum from patients with MCI, monitoring proliferation, cell count, and apoptotic cell death to predict AD conversion, allowing for pre-symptomatic diagnosis and therapeutic assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to identify AD patients, then diagnosis can be made, but the diagnosis occurs after significant hippocampal damage has already occurred, preventing pre-symptomatic intervention
Solution Approach 1:
The assay enables preliminary detection of AD risk by measuring hippocampal neurogenesis markers in MCI patients before clinical diagnosis occurs. By detecting biochemical changes in cerebrospinal fluid that precede symptomatic manifestation, the system allows therapeutic intervention to be initiated pre-symptomatically, addressing the contradiction between early detection and timely treatment.
2Productivity
If MCI patients are included in clinical trials, then more patients can be studied, but the ability to evaluate therapy efficacy is compromised due to uncertain disease progression
Solution Approach 1:
The assay provides a feedback mechanism to stratify MCI patients into high-risk and low-risk groups based on their hippocampal neurogenesis status. This feedback allows clinical trials to selectively enroll only those MCI patients likely to progress to AD, maintaining high enrollment numbers while ensuring reliable efficacy evaluation through homogeneous patient selection.
3Measurement precision
If direct measurement of hippocampal neurogenesis is attempted in living individuals, then accurate assessment of HN function is possible, but no direct measurement tools currently exist
Solution Approach 1:
The assay uses cerebrospinal fluid as an intermediary medium to indirectly measure hippocampal neurogenesis. By detecting bioactive molecules in CSF that reflect neuronal proliferation and differentiation processes, the system bridges the gap between inaccessible in-situ HN measurement and available non-invasive sampling methods.
Data Source
AI summary
The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.